Valneva SE business relationships
Companies named in Valneva SE’s 20-F filed 2026-03-17, and public companies whose annual reports name Valneva SE. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.7 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Valneva SE’s annual report 10
“Therefore, for the year ended December 31, 2022, the accumulated revenue recognized since the inception of the agreement with Pfizer amounting to €45.9 million was reversed as other revenues from contracts with customers.” SEC filing
“In regards to our Borrelia vaccine candidate VLA15 which is currently licensed to Pfizer, as of December 31, 2025, we own a patent family which includes 8 issued U.S. patents, 1 pending U.S. patent application, and 2 European patents that are validated, one in 38 of the European Patent Convention me...” SEC filing
“Other Revenues and Refund Liabilities - Research Collaboration and License Agreement with Pfizer” SEC filing
“We are awaiting results from the pivotal, placebo-controlled efficacy clinical trial, "Vaccine Against Lyme for Outdoor Recreationists (VALOR)" in the first half of 2026, conducted by our partner Pfizer.” SEC filing
“To monitor the credit quality of our counterparts, we rely on credit ratings as published by specialized rating agencies such as Standard & Poor's, Moody's, and Fitch.” SEC filing
“Master Collaboration and License Agreement, dated December 16, 2024, by and between the Serum Institute of India Private Limited and Valneva Austria GmbH” SEC filing
“...Phase 3 clinical trial costs performed by Pfizer, and €6.5 million (all non-current) related to the expected payment to GSK related to the termination of the strategic alliance agreement in 2019, and €1.1 million (all current) related to refund liabilities to customers related to rebate and refund p...” SEC filing
“In September 2022, we announced a marketing and distribution agreement with VBI Vaccines Inc. to commercialize their Hepatitis B vaccine PreHevbri in the United Kingdom, Sweden, Norway, Denmark, Finland, Belgium, and the Netherlands which ended in 2024.” SEC filing
“In August 2024, we entered into a collaboration with LimmaTech Biologics AG for the development of S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria.” SEC filing
“In November 2021, Valneva Austria GmbH entered into a non-exclusive commercial manufacturing services agreement, or the IDT Agreement, with IDT Biologika GmbH, or IDT, pursuant to which IDT would provide contract manufacturing services under separate product schedules.” SEC filing
Companies whose annual reports name Valneva SE 2
“(c) VLA15 is being developed in collaboration with Valneva SE.” SEC filing
“Sales of products supplied by Biotest AG, Kedrion, Chiesi Farmaceutici S.p.A, Bio Products Laboratories ("BPL") Valneva SE and Mabxience, which are” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.